The therapeutic potential of cannabinoids for movement disorders
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid‐based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid‐based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders. © 2015 International Parkinson and Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000 · cited 1×
“Cannabinoidbased medicines, such as nabilone, dronabinol, and Sativex, are now approved for clinical indications, including pain, anorexia, spasticity, and chemotherapy-induced nausea and Epidiolex recently obtained orphan drug status for Dravet syndrome.(6,7) Preclinical research suggests that cannabinoids have sympt…”
BackgroundZajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827 · cited 1×
“5 mg given twice-daily) versus placebo showed no difference in patient ratings of tremor as a secondary outcome.(103) Given the consistent lack of response to cannabinoids in patients suffering from MS-related tremor, AAN evidence-based guidelines state that THC and oral cannabis extract are probably ineffective for r…”
BackgroundEndocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
Kreitzer, A. C., & Malenka, R. C. (2007) · Nature · doi:10.1038/nature05506 · Cited by 735
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728 · cited 1×
“CB2 agonists exert anti-inflammatory effects by inhibiting reactive microglia and cytokine release.(19,26,38,39) Last, CB1 agonists reduce excitotoxicity by suppressing glutamatergic activity, subsequent calcium ion influx, and nitric oxide production.”
BackgroundThe Pharmacologic and Clinical Effects of Medical Cannabis
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., et al. (2009) · Brain · doi:10.1093/brain/awp239 · Cited by 382
Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550355 · Cited by 365 · cited 1×
“Most recently, 21 PD patients were randomized to placebo, CBD 75 mg/day, or CBD 300 mg/day for a 6-week trial.(95) No significant changes were found for the total UPDRS or any subscales or measures of neuroprotection (serum brain-derived neurotrophic factor [BDNF] levels or putamen magnetic resonance spectroscopy).”
BackgroundCannabidiol for the treatment of psychosis in Parkinson's disease
Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355 · cited 1×
“Regarding nonmotor symptoms, a small (N 5 6) 4-week open-label study of CBD for psychosis in PD found improvements on the Brief Psychiatric Rating Scale and Parkinson Psychosis Questionnaire and another case series (N 5 4) reported benefits for rapid eye movement sleep behavior disorder (RBD).(87,90) However, a case s…”
BackgroundCannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001) · Neurology · doi:10.1212/wnl.57.11.2108 · Cited by 349 · cited 1×
“03 mg/kg of nabilone, a CB1 and CB2 agonist for LID given in a split dose 12 and 1 hour before an Ldopa challenge.(94) They found a significant reduction in LID versus placebo on the Rush Dyskinesia Disability Scale (RDS) and total LID time.”
MethodGarcía-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.063 · Cited by 320 · cited 2×
“Cannabinoids are capable of reducing oxidative damage by acting as scavengers of reactive oxygen species and enhancing endogenous antioxidant defenses.37 This property appears to be independent of CB1 and CB2 receptor modulation and restricted to certain cannabinoids, including CBD, THC, cannabinol, CP55,940, and the…”
BackgroundCollin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., et al. (2010) · Neurological Research · doi:10.1179/016164109x12590518685660 · Cited by 283 · cited 1×
“A large (N 5 337) 8-week double-blind, randomized, placebocontrolled trial of up to 24 actuations per day of oral nabiximols spray (65 mg of THC, 60 mg of CBD) evaluated tremor as a secondary outcome with an index score and patient global impression of change and reported no effect on tremor.(101) Another large (N 5 3…”
MethodMuller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0417 · Cited by 270
Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial
Müller-Vahl, K., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-25028 · Cited by 256
Sagredo, O., González, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres‐Becker, I., Romero, J. P., Tolón, R. M., Mechoulam, R., Brouillet, E., et al. (2009) · Glia · doi:10.1002/glia.20838 · Cited by 201
Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147
The clinical features of psychogenic movement disorders resembling tics
Baizabal-Carvallo, J. F., & Jankovic, J. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305594 · Cited by 125 · cited 1×
“Marijuana may be effective for psychogenic symptoms, as illustrated by a report by Sanjay Gupta, called “Weed,” which featured a 19-year-old young man who, after 7 minutes of “convulsing” with “myoclonus–diaphragmatic flutter,” resembling psychogenic tic or tremor, had a sudden resolution of the movement, respiratory,…”
BackgroundSelf-citationSagredo, O., Pazos, M. R., Satta, V., Ramos, J. A., Pertwee, R. G., & Fernández‐Ruiz, J. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22682 · Cited by 105
Cited by
Iannotti, F. A., Di Marzo, V., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357
Lim, K., See, Y. M., & Lee, J. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.4.301 · Cited by 166
Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
Peball, M., Krismer, F., Knaus, H., Djamshidian, A., Werkmann, M., Carbone, F., Ellmerer, P., Heim, B., Marini, K., Valent, D., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25864 · Cited by 123
“The ECS plays a significant part in motor control and the regulation of various non-motor functions, including mood, attention and concentration, eating habits, sleep, and pain.(7,14) In animal models, a high amount of cannabinoid 1 receptors is found in presynaptic nerve terminals of gamma-Aminobutyric acid-ergic syn…”
BackgroundResultParkinson disease psychosis: from phenomenology to neurobiological mechanisms
Pagonabarraga, J., Bejr-Kasem, H., Martinez-Horta, S., & Kulisevsky, J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00918-8 · Cited by 69
Metadata
- Authors
- Kluger, B., Triolo, P., Jones, W., & Jankovic, J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2015-02-04
- Volume
- 30
- Issue
- 3
- Pages
- 313-327
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2095622912
- Cited by
- 122
- References
- 21
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.